• Earlier in April 2026, Ascendis Pharma reported Phase 2 COACH trial data showing that once-weekly TransCon CNP plus TransCon hGH improved growth and key skeletal measures in children with achondroplasia, while YUVIWEL (TransCon CNP) won U.S. orphan drug exclusivity and became commercially available.
• The combination of stronger clinical evidence in achondroplasia and the launch of YUVIWEL with orphan exclusivity enhances Ascendis’s rare disease treatment profile and potential revenue durability in this indication.
• We’ll now examine how YUVIWEL’s orphan exclusivity and U.S. launch could influence Ascendis’s existing investment narrative around its TransCon platform.

Find 59 companies with promising cash flow potential yet trading below their fair value.

Ascendis Pharma Investment Narrative Recap

To own Ascendis, you really need to believe the TransCon platform can support multiple durable rare disease franchises, not just one-off products. In the near term, YUVIWEL’s U.S. launch and orphan exclusivity strengthen the achondroplasia pillar, while COACH combo data reinforce the platform story. The key catalyst remains execution on commercial uptake and confirmatory trials for YUVIWEL, against the ongoing risk that high R&D and SG&A spending keep profitability and cash generation under pressure.

The most relevant recent announcement here is the FDA’s grant of orphan drug exclusivity and commercial availability for YUVIWEL in the U.S. This secures a defined exclusivity window to build a recurring revenue base in achondroplasia, which could ease some concerns about revenue concentration in YORVIPATH and SKYTROFA. At the same time, it puts more focus on whether Ascendis can control costs as the company layers another rare disease launch on top of its existing commercial footprint.

Yet even with these positives, investors should still pay close attention to the risk that ongoing cash burn and high operating costs could begin to weigh more heavily on...

Ascendis Pharma's narrative projects €2.5 billion revenue and €1.1 billion earnings by 2029. This requires 51.6% yearly revenue growth and about a €1.3 billion earnings increase from -€228.0 million today.

Uncover how Ascendis Pharma's forecasts yield a $289.37 fair value, a 18% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts already expected revenue to reach about €2.9 billion and earnings €1.6 billion by 2029, while also warning that rising R&D and SG&A costs could strain cash burn if growth slips, so this new achondroplasia data and YUVIWEL launch may well shift how you weigh those upside targets against execution risk.

Explore 4 other fair value estimates on Ascendis Pharma - why the stock might be worth just $248.32!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Ascendis Pharma research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Ascendis Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ascendis Pharma's overall financial health at a glance.

Searching For A Fresh Perspective?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.
• Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.